Navigating FDA's rules to get a fixed-dose combination therapy for chronic obstructive pulmonary disease approved required a large study and a specific population. When GlaxoSmithKline designed the ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using TRELEGY ELLIPTA? TRELEGY ELLIPTA contains the active ...
GlaxoSmithKline has so much riding on the success of its new 3-in-1 COPD drug, Trelegy Ellipta, that last month the company rejiggered its sales and marketing operations so it could pour more ...
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a prescription drug that’s used to treat COPD and asthma. Trelegy Ellipta comes as an inhaler. To learn ...
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can cause side effects that range from mild to serious. More common side effects include headache and ...
Critical errors made when using inhalers, which significantly reduce or completely inhibit drug delivery, have been identified for various inhalation devices. Between 36 and 49% of patients with COPD ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback